1043 related articles for article (PubMed ID: 18397236)
21. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
Corpechot C; Chazouillères O; Poupon R
J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
[TBL] [Abstract][Full Text] [Related]
22. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
[TBL] [Abstract][Full Text] [Related]
23. [The diagnostic value of serum hyaluronic acid, 7S domain of type IV collagen and AST/ALT ratio as markers of hepatic fibrosis in chronic hepatitis B and cirrhosis patients].
Park JH; Park CK; Kim ES; Park SY; Jo CM; Tak WY; Kweon YO; Kim SK; Choi YW
Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):79-88. PubMed ID: 12824747
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
Lee YM; Kaplan MM
Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
[TBL] [Abstract][Full Text] [Related]
25. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis.
Parés A; Deulofeu R; Giménez A; Caballería L; Bruguera M; Caballería J; Ballesta AM; Rodés J
Hepatology; 1996 Dec; 24(6):1399-403. PubMed ID: 8938169
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
27. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
[TBL] [Abstract][Full Text] [Related]
29. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
Joshi S; Cauch-Dudek K; Wanless IR; Lindor KD; Jorgensen R; Batts K; Heathcote EJ
Hepatology; 2002 Feb; 35(2):409-13. PubMed ID: 11826416
[TBL] [Abstract][Full Text] [Related]
30. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.
Kelleher TB; Mehta SH; Bhaskar R; Sulkowski M; Astemborski J; Thomas DL; Moore RE; Afdhal NH
J Hepatol; 2005 Jul; 43(1):78-84. PubMed ID: 15894397
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
32. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis.
Kumagi T; Guindi M; Fischer SE; Arenovich T; Abdalian R; Coltescu C; Heathcote EJ; Hirschfield GM
Am J Gastroenterol; 2010 Oct; 105(10):2186-94. PubMed ID: 20502446
[TBL] [Abstract][Full Text] [Related]
33. The use of ursodeoxycholic acid in patients with primary biliary cirrhosis: sense or nonsense.
Van Den Bogaert E; Francque S; Pelckmans P; Michielsen P
Acta Gastroenterol Belg; 2003; 66(4):283-7. PubMed ID: 14989050
[TBL] [Abstract][Full Text] [Related]
34. Bezafibrate treatment: a new medical approach for PBC patients?
Kanda T; Yokosuka O; Imazeki F; Saisho H
J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
[TBL] [Abstract][Full Text] [Related]
35. Overlap of primary biliary cirrhosis and autoimmune hepatitis: Characteristics, therapy, and long term outcomes.
Yokokawa J; Saito H; Kanno Y; Honma F; Monoe K; Sakamoto N; Abe K; Takahashi A; Yokokawa H; Ohira H
J Gastroenterol Hepatol; 2010 Feb; 25(2):376-82. PubMed ID: 19817953
[TBL] [Abstract][Full Text] [Related]
36. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
[TBL] [Abstract][Full Text] [Related]
38. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Patel T; Jorgensen RA; Therneau TM; Lindor KD
Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
[TBL] [Abstract][Full Text] [Related]
39. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
[TBL] [Abstract][Full Text] [Related]
40. The natural history of PBC: has it changed?
Lee YM; Kaplan MM
Semin Liver Dis; 2005 Aug; 25(3):321-6. PubMed ID: 16143947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]